Physician profile
Anna Perrone
NPI 1316442932
$2,596.94
in general payments reported to CMS, 2019-2025
19 companies · $977 in 2025
The $977 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $397 · 2023: $531 · 2024: $549 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $419.53 | 2024-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $398.56 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $395.52 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.30 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $225.98 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.60 | 2022-2025 | Jardiance, Ofev |
| Abbvie INC. | $153.28 | 2022-2025 | |
| Dexcom, INC. | $91.10 | 2021 | |
| Amneal Pharmaceuticals LLC | $84.32 | 2025 | Unithroid |
| Glaxosmithkline, LLC. | $69.35 | 2023-2025 | Shingrix |
| Kowa Pharmaceuticals America, INC. | $57.28 | 2025 | Zoryve |
| Currax Pharmaceuticals LLC | $50.84 | 2022-2024 | Contrave |
| Amgen INC. | $41.42 | 2025 | Otezla, Repatha |
| Ardelyx, INC. | $26.56 | 2025 | Ibsrela |
| Seqirus USA INC | $26.25 | 2025 | Fluad, Flucelvax |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.97 | 2021 | |
| Pfizer INC. | $23.67 | 2025 | |
| Baxter Healthcare | $17.99 | 2022 | |
| Welch Allyn | $15.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Perrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.